Key points A 68-year-old woman presented to the emergency department of a rural hospital in southern Alberta 1 hour after acute onset of speech difficulties and weakness in her right upper and lower ...

TNKase is administered as a single intravenous bolus over 5 seconds. The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in ...

Please provide your email address to receive an email when new articles are posted on . Researchers engaged in a secondary analysis of the ESCAPE clinical trial in patients with acute ischemic stroke.

Background The presence of a coincident intracranial aneurysm (CIA) on the target vessel of patients undergoing mechanical thrombectomy (MT) for acute ischemic stroke (AIS) poses challenges, as the ...

An earlier start to anticoagulation after an acute ischemic stroke for patients found to have atrial fibrillation appeared safe and possibly improved outcomes, according to the randomized ELAN trial.

A new analysis supports the use of intravenous (IV) tenecteplase over IV alteplase (tissue plasminogen activator) for treatment of acute ischemic stroke. The analysis found that patients with ischemic ...

The growth of the acute ischemic stroke market is expected to be driven primarily by increased awareness of symptoms, advances in acute stroke care, and a robust pipeline of potential candidates such ...

Tenecteplase for acute ischemic stroke provided similar safety and effectiveness outcomes as alteplase, a new study showed, suggesting the drug is a viable alternative treatment. This comparative ...

Please provide your email address to receive an email when new articles are posted on . TNKase is the first stroke treatment approved by the FDA in almost 30 years, the manufacturer said. It is ...

In a randomized, sham-controlled study published in the Journal of the American Medical Association (JAMA), researchers investigated the effect of remote ischemic conditioning (RIC) on functional ...